Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase

Journal of Medicinal Chemistry

Volumn 52, Issue 21, 2009, Pages 6539-6542

  Deng, Lisheng ^a   Sundriyal, Sandeep ^a   Rubio, Valentina ^b   Shi, Zheng Zheng ^b   Song, Yongcheng ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXY DEXTRO XYLULOSE 5 PHOSPHATE REDUCTOISOMERASE; AMPICILLIN; FOSMIDOMYCIN; ISOMERASE; KANAMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; IC 50; LIPOPHILICITY; NONHUMAN;

ALDOSE-KETOSE ISOMERASES; ANTI-BACTERIAL AGENTS; CELL LINE; CELL MEMBRANE PERMEABILITY; CHELATING AGENTS; DRUG RESISTANCE, BACTERIAL; FOSFOMYCIN; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MAGNESIUM; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MULTIENZYME COMPLEXES; OXIDOREDUCTASES; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71049170515     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9012592     Document Type: Article

References (33)

1. Leeb, M. Antibiotics: a shot in the arm. Nature 2004, 431, 892-893.
2. Nathan, C. Antibiotics at the crossroads. Nature 2004, 431, 899-902.
3. (a) Rodriguez-Concepcion, M. The MEP pathway: a new target for the development of herbicides, antibiotics and antimalarial drugs. Curr. Pharm. Des. 2004, 10, 2391-2400.
4. (b) Testa, C. A.; Brown, M. J. The methylerythritol phosphate pathway and its significance as a novel drug target. Curr. Pharm. Biotechnol. 2003, 4, 248-259.
5. Mine, Y.; Kamimura, T.; Nonoyama, S.; Nishida, M.; Goto, S.; Kuwahara, S. In vitro and in vivo antibacterial activities of FR-31564, a new phosphonic acid antibiotic. J. Antibiot. (Tokyo) 1980, 33, 36-43.
6. Kuzuyama, T.; Shimizu, T.; Takahashi, S.; Seto, H. Fosmidomycin, a specific inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in the nonmevalonate pathway for terpenoid biosynthesis. Tetrahedron Lett. 1998, 39, 7913-7916.
7. (a) Jomaa, H.; Wiesner, J.; Sanderbrand, S.; Altincicek, B.; Weidemeyer, C.; Hintz, M.; Turbachova, I.; Eberl, M.; Zeidler, J.; Lichtenthaler, H. K.; Soldati, D.; Beck, E. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 1999, 285, 1573-1576. (Pubitemid 29420582)
8. (b) Missinou, M. A.; Borrmann, S.; Schindler, A.; Issifou, S.; Adegnika, A. A.; Matsiegui, P. B.; Binder, R.; Lell, B.; Wiesner, J.; Baranek, T.; Jomaa, H.; Kremsner, P. G. Fosmidomycin for malaria. Lancet 2002, 360, 1941-1942.
9. (a) Dhiman, R. K.; Schaeffer, M. L.; Bailey, A. M.; Testa, C. A.; Scherman, H.; Crick, D. C. 1-Deoxy-D-xylulose 5-phosphate reductoisomerase (IspC) from Mycobacterium tuberculosis: towards understanding mycobacterial resistance to fosmidomycin. J. Bacteriol. 2005, 187, 8395-8402.
10. (b) Brown, A. C.; Parish, T. DXR is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake. BMC Microbiol. 2008, 8, 78-86. (Pubitemid 351793258)
11. For development based on fosmidomycin, see the following: (a) Shtannikov, A. V.; Sergeeva, E. E.; Biketov, S. F.; Ostrovskii, D. N. Evaluation of in vitro antibacterial activity of fosmidomycin and its derivatives. Antibiot. Khimioter. 2007, 52, 3-9.
12. (b) Kuntz, L.; Tritsch, D.; Grosdemange-Billiard, C.; Hemmerlin, A.; Willem, A.; Bach, T. J.; Rohmer, M. Isoprenoid biosynthesis as a target for antibacterial and antiparasitic drugs: phosphonohydroxamic acids as inhibitors of deoxyxylulose phosphate reducto-isomerase. Biochem. J. 2005, 386, 127-135. (Pubitemid 40289232)
13. (c) Merckle, L.; de Andres-Gomez, A.; Dick, B.; Cox, R. J.; Godfrey, C. R. A fragment-based approach to understanding inhibition of 1-deoxy-D-xylulose- 5-phosphate reductoisomerase. ChemBioChem 2005, 6, 1866-1874.
14. (d) Munos, J. W.; Pu, X.; Liu, H. W. Synthesis and analysis of a fluorinated product analogue as an inhibitor for 1-deoxy-D-xylulose 5-phosphate reductoisomerase. Bioorg. Med. Chem. Lett. 2008, 18, 3090-3094.
15. (e) Ortmann, R.; Wiesner, J.; Silber, K.; Klebe, G.; Jomaa, H.; Schlitzer, M. Novel deoxyxylulosephosphate-reductoisomerase inhibitors: fosmidomycin derivatives with spacious acyl residues. Arch. Pharm. (Weinheim, Ger.) 2007, 340, 483-490.
16. (f) Silber, K.; Heidler, P.; Kurz, T.; Klebe, G. AFMoC enhances predictivity of 3D QSAR: a case study with DOXP-reductoisomerase. J. Med. Chem. 2005, 48, 3547-3563.
17. (g) Woo, Y. H.; Fernandes, R. P.; Proteau, P. J. Evaluation of fosmidomycin analogs as inhibitors of the Synechocystis sp. PCC6803 1-deoxy-D-xylulose 5-phosphate reductoisomerase. Bioorg. Med. Chem. 2006, 14, 2375-2385.
18. (h) Kurz, T.; Schlüter, K.; Kaula, U.; Bergmann, B.; Walter, R. D.; Geffken, D. Synthesis and antimalarial activity of chain substituted pivaloyloxymethyl ester analogues of fosmidomycin and FR900098. Bioorg. Med. Chem. 2006, 14, 5121-5135.
19. (i) Kurz, T.; Schlüter, K.; Pein, M.; Behrendt, C.; Bergmann, B.; Walter, R. D. Conformationally restrained aromatic analogues of fosmidomycin and FR900098. Arch. Pharm. Chem. Life Sci. 2007, 340, 339-344.
20. (j) Haemers, T.; Wiesner, J.; Van Poecke, S.; Goeman, J.; Henschker, D.; Beck, E.; Jomaa, H.; Van Calenbergh, S. Synthesis of R-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 1888-1891.
21. (k) Devreux, V.; Wiesner, J.; Jomaa, H.; Rozenski, J.; Van der Eycken, J.; Van Calenbergh, S. Divergent strategy for the synthesis of α-aryl-substituted fosmidomycin analogues. J. Org. Chem. 2007, 72, 3783-3789.
22. For non-fosmidomycin-like inhibitors, see the following: (l) Yajima, S.; Hara, K.; Sanders, J. M.; Yin, F.; Ohsawa, K.; Wiesner, J.; Jomaa, H.; Oldfield, E. Crystallographic structures of two bisphosphonate:1-deoxyxylulose-5- phosphate reductoisomerase complexes. J. Am. Chem. Soc. 2004, 126, 10824-10825.
23. For high-throughput screening, see the following: (m) Gottlin, E. B.; Benson, R. E.; Conary, S.; Antonio, B.; Duke, K.; Payne, E. S.; Ashraf, S. S.; Christensen, D. J. High-throughput screen for inhibitors of 1-deoxy-D-xylulose 5-phosphate reductoisomerase by surrogate ligand competition. J. Biomol. Screening 2003, 8, 332-339.
24. Yajima, S.; Hara, K.; Iino, D.; Sasaki, Y.; Kuzuyama, T.; Ohsawa, K.; Seto, H. Structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in a quaternary complex with a magnesium ion, NADPH and the antimalarial drug fosmidomycin. Acta Crystallogr., Sect. F 2007, 63, 466-470. (Pubitemid 46878873)
25. MacSweeney, A.; Lange, R.; Fernandes, R. P.; Schulz, H.; Dale, G. E.; Douangamath, A.; Proteau, P. J.; Oefner, C. The crystal structure of E. coli 1-deoxy-D-xylulose-5-phosphate reductoisomerase in a ternary complex with the antimalarial compound fosmidomycin and NADPH reveals a tight-binding closed enzyme conformation. J. Mol. Biol. 2005, 345, 115-127.
26. Athavale, V. T.; Prabhu, L. H.; Vartak, D. G. Solution stability constants of some metal complexes of derivatives of catechol. J. Inorg. Nucl. Chem. 1966, 28, 1237-1249.
27. Agrawal, Y. K.; Roshania, R. D. Theomodynamic metal-ligand stability constants of alkali eath metals with N-p-chlorophenylbenzohydroxamic acid. Z. Phys. Chem. (Leipzig) 1982, 263, 822-826.
28. www.schrodinger.com.
29. For hydroxamate based matrix metalloproteinase inhibitors, see the following: (a) Wada, C. K. The evolution of the matrix metalloproteinase inhibitor drug discovery program at abbott laboratories. Curr. Top. Med. Chem. 2004, 4, 1255-1267.
30. For hydroxamate based histone deacetylase inhibitors, see the following: (b) Sanderson, L.; Taylor, G. W.; Aboagye, E. O.; Alao, J. P.; Latigo, J. R.; Coombes, R. C.; Vigushin, D. M. Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin A after intraperitoneal administration to mice. Drug Metab. Dispos. 2004, 32, 1132-1138.
31. (a) Jacobsen, F. E.; Lewis, J. A.; Cohen, S. M. The design of inhibitors for medicinally relevant metalloproteins. ChemMedChem 2007, 2, 152-171.
32. (b) Jacobsen, F. E.; Lewis, J. A.; Cohen, S. M. A new role for old ligands: discerning chelators for zinc metalloproteinases. J. Am. Chem. Soc. 2006, 128, 3156-3157.
33. See Supporting Information for detailed synthesis and references.